A high-affinity CDR-grafted antibody against influenza A H5N1 viruses recognizes a conserved epitope of H5 hemagglutinin

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Xiong, Feifei ^a,b   Xia, Liliang ^b   Wang, Jingfang ^c   Wu, Biao ^b   Wang, Dengyu ^b   Yuan, Longfang ^b   Cheng, Yating ^b   Zhu, Hongying ^b   Che, Xiaoyan ^d   Zhang, Qinghua ^a   Zhao, Guoping ^b   Wang, Ying ^b,e  

^a TONGJI UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c Chinese National Human Genome Center at Shanghai   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY H5M9; EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS ANTIBODY; COMPLEMENTARITY DETERMINING REGION; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG POTENCY; EPITOPE MAPPING; IMMUNOGENICITY; IN VITRO STUDY; INFLUENZA VIRUS A H5N1; NONHUMAN; SEQUENCE ANALYSIS; VACCINATION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; COMPLEMENTARITY DETERMINING REGIONS; CONSERVED SEQUENCE; EPITOPE MAPPING; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION;

EID: 84895874819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088777     Document Type: Article

References (57)

1. Chen H, Smith GJ, Li KS, Wang J, Fan XH, et al. (2006) Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 103: 2845-2850.
2. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, et al. (2004) Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430: 209-213. (Pubitemid 38902429)
3. Smith GJ, Fan XH, Wang J, Li KS, Qin K, et al. (2006) Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A 103: 16936-16941. (Pubitemid 44737356)
4. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO. Available: http://www.who.int/ influenza/human-animal-interface/H5N1-cumulative-table-archives/en/index.html. Accessed 26 April 2013.
5. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y (2008) Human infection with highly pathogenic H5N1 influenza virus. Lancet 371: 1464-1475. (Pubitemid 351618340)
6. Pappaioanou M (2009) Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic? Comp Immunol Microbiol Infect Dis 32: 287-300.
7. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47: 57-77.
8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145: 599-609. (Pubitemid 46780940)
9. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357: 1450-1451. (Pubitemid 47535608)
10. Shen S, Mahadevappa G, Oh HL, Wee BY, Choi YW, et al. (2008) Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J Med Virol 80: 1972-1983.
11. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26: 5393-5399.
12. Lim AP, Wong SK, Chan AH, Chan CE, Ooi EE, et al. (2008) Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virol J 5: 80.
13. Wang SF, Chen KH, Thitithanyanont A, Yao L, Lee YM, et al. (2009) Generating and characterizing monoclonal and polyclonal antibodies against avian H5N1 hemagglutinin protein. Biochem Biophys Res Commun 382: 691-696.
14. Sun L, Lu X, Li C, Wang M, Liu Q, et al. (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4: e5476.
15. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178.
16. Knossow M, Gaudier M, Douglas A, Barrere B, Bizebard T, et al. (2002) Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302: 294-298. (Pubitemid 35373857)
17. Eisen MB, Sabesan S, Skehel JJ, Wiley DC (1997) Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin- sialyloligosaccharide complexes determined by X-ray crystallography. Virology 232: 19-31. (Pubitemid 27244459)
18. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531-569.
19. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, et al. (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 83: 2553-2562.
20. Fleury D, Daniels RS, Skehel JJ, Knossow M, Bizebard T (2000) Structural evidence for recognition of a single epitope by two distinct antibodies. Proteins 40: 572-578.
21. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
22. Seccamani E, Tattanelli M, Mariani M, Spranzi E, Scassellati GA, et al. (1989) A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int J Rad Appl Instrum B 16: 167-170. (Pubitemid 19098504)
23. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, et al. (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191-1197. (Pubitemid 20219494)
24. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, et al. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86: 10029-10033. (Pubitemid 20030769)
25. Li B, Wang H, Zhang D, Qian W, Hou S, et al. (2007) Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. Biochem Biophys Res Commun 357: 951-956. (Pubitemid 46693663)
26. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078. (Pubitemid 41486385)
27. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525. (Pubitemid 16052256)
28. Paquet ME, Leach MR, Williams DB (2005) In vitro and in vivo assays to assess the functions of calnexin and calreticulin in ER protein folding and quality control. Methods 35: 338-347. (Pubitemid 40445366)
29. Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antibodies 10: 127-142. (Pubitemid 34258592)
30. Li J, Wang Y, Liang Y, Ni B,Wan Y, et al. (2009) Fine antigenic variation within H5N1 influenza virus hemagglutinin's antigenic sites defined by yeast cell surface display. Eur J Immunol 39: 3498-3510.
31. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C (1991) Sequences of Proteins of Immunological Interest, Fifth ed. Bethesda, MD: United States Department of Health and Human Services.
32. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4: 773-783.
33. Wright A, Shin SU, Morrison SL (1992) Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12: 125-168. (Pubitemid 23014487)
34. Nakatani T, Lone YC, Yamakawa J, Kanaoka M, Gomi H, et al. (1994) Humanization of mouse anti-human IL-2 receptor antibody B-B10. Protein Eng 7: 435-443. (Pubitemid 24063144)
35. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A (2007) Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A 104: 246-251. (Pubitemid 46068017)
36. Khurana S, Suguitan AL, Jr., Rivera Y, Simmons CP, Lanzavecchia A, et al. (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 6: e1000049.
37. Hu H, Voss J, Zhang G, Buchy P, Zuo T, et al. (2012) A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 86: 2978-2989.
38. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
39. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378. (Pubitemid 11135143)
40. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, et al. (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 81: 1779-1783. (Pubitemid 14149547)
41. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS, et al. (2002) Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 83: 2497-2505.
42. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shilov AA, et al. (2007) Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911-12917. (Pubitemid 350156928)
43. Cusick MF, Wang S, Eckels DD (2009) In vitro responses to avian influenza H5 by human CD4 T cells. J Immunol 183: 6432-6441.
44. Yang J, Gebe JA, Huston L, James E, Tan V, et al. (2009) H5N1 strain-specific hemagglutinin CD4+ T cell epitopes restricted by HLA DR4. Vaccine 27: 3862-3869.
45. Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, et al. (2009) Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum Immunol 70: 711-721.
46. Wang SF, Yao L, Liu SJ, Chong P, Liu WT, et al. (2010) Identifying conserved DR1501-restricted CD4(+) T-cell epitopes in avian H5N1 hemagglutinin proteins. Viral Immunol 23: 585-593.
47. Zhu X, Guo YH, Jiang T, Wang YD, Chan KH, et al. (2013) A Unique and Conserved Neutralization Epitope in H5N1 Influenza Viruses Identified by an Antibody against the A/Goose/Guangdong/1/96 Hemagglutinin. J Virol 87: 12619-12635.
48. Ofran Y, Schlessinger A, Rost B (2008) Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes. J Immunol 181: 6230-6235.
49. Collis AV, Brouwer AP, Martin AC (2003) Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 325: 337-354. (Pubitemid 36062692)
50. Almagro JC (2004) Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J Mol Recognit 17: 132-143.
51. Workman CJ, Pfund WP, Voss EW, Jr. (1997) Dual specificity and the formation of stable autoimmune complexes. J Mol Recognit 10: 225-234. (Pubitemid 28202956)
52. Workman CJ, Pfund WP, Voss EW, Jr. (1998) Two dual-specific (anti-IgG and anti-dsDNA) monoclonal autoantibodies derived from the NZB/NZW F1 recognize an epitope in the hinge region. J Protein Chem 17: 599-606. (Pubitemid 28554840)
53. Laisney IL, Strosberg AD (1999) Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1). Immunol Lett 67: 185-192. (Pubitemid 29219763)
54. Mazor Y, Keydar I, Benhar I (2005) Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity. Mol Immunol 42: 55-69. (Pubitemid 39360927)
55. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 27-38.
56. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802. (Pubitemid 43078511)
57. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E (1991) Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9: 303-308.